RN7SL759P

Across TCGA pan-cancer cohorts, RN7SL759P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RN7SL759P data layer compared with 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher RN7SL759P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL759P expression acts as an unfavorable survival marker.

PAAD are the cancer types where RN7SL759P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RN7SL759P–PAAD (DFS)

Open the PAAD breakdown →